-
FDA sets May 2027 decision date on AMT-130 gene therapy for HD
4 min read
Latest News
-
October 2026: This Month in Huntington’s Disease Research
4 min read
From sticky thoughts and pigs that model HD to DNA repair and promising drug trial results, October brought fresh insights into HD. Here’s what you might have missed!
-
Pfizer Amaryllis trial ends in disappointment: no improvement in Huntington's disease symptoms
4 min read
Pfizer announces the 'Amaryllis' trial of a PDE-10 inhibitor drug failed to improve symptoms of HD
-
Important advances in next generation genome editing tools for Huntington's Disease
13 min read
Work with genome editing techniques (zinc fingers and CRISPR) brings these tools closer to use in HD clinical trials
-
Sorry folks, the PRIDE-HD trial did NOT show that Pridopidine slows the progression of Huntington's disease
13 min read
HDBuzz helps untangle some bold claims about the just-announced results of the PRIDE-HD trial of pridopidine in HD
-
EuroBuzz 2016: The Euro-HD Network Meeting in The Hague
21 min read
All our tweets from #EHDN2016 in one mega-article
-
Ultra-rare mutations highlight the importance of the HD gene in brain development
8 min read
New technology enables researchers to find ultra-rare mutations in the HD gene, distinct from the one causing HD
-
A support system gone wrong – glial cells contribute to HD symptoms
7 min read
An elegant new study helps determine how much brain cells called glia matter to HD symptoms
-
Early exposure to the HD protein may cause life-long symptoms
8 min read
A surprising new mouse study suggests the mutant HD gene may do some of its damage during embryonic development
-
Electron beam snaps best images yet of Huntington's disease protein
6 min read
Electrons enable huntingtin protein, the cause of Huntington's disease, to be visualised at highest resolution ever
-
Planting trees together: The 2016 Huntington's Disease Society of America Convention
6 min read
HDBuzz summarizes the science from an unusually large and energized @HDSA convention in Baltimore
-
Huntingtin takes a trip: harmful proteins pass between brain cells
7 min read
Harmful misfolded huntingtin can travel between brain cells via messenger particles called exosomes
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
